Detail

Chr	NA
start	NA
end	NA
ID	NA
miRNA_name	hsa-miR-5119
methods	qRT-PCR,luciferase assays,etc.
regulated	differential expression
Function Description	In summary, this study, for the first time, develops a novel immunotherapy using miR-5119 mimic-engineered DCs for treatment of breast cancer. Engineering DCs with miR-5119 simultaneously repressed multiple negative regulatory mole-cules, including IR ligands such as PD-L1 and IDO2 in DCs which, in turn, stimulate anti-tumor immune response and upregulate cytokine production while simultaneously reduc-ing IR expression in, and apoptosis of, T cells. Furthermore, treatment with miR-5119 mimic-engineered DC vaccine dis-played pre-clinical efficacy in controlling mouse syngeneic homograft tumor growth, in association with reduced T cell apoptosis and enhanced anti-breast cancer tumor immunity. This study reveals a new strategy for miRNA/DC-based immunotherapy and highlights potential to enhance therapy for breast and other cancers.
PMID	32076794
year	2020
Title	miRNA-5119 regulates immune checkpoints in dendritic cells to enhance breast cancer immunotherapy.
drug	X
circulating	X
survival	X